Pharmidex Pharmaceutical Services Limited

Immunotherapy, the modulation of a patient's immune system to fight against diseases such as cancer, holds great promise but is still far from being widely usable for solid tumors. This is due to several reasons: cancers are good at evading the host immune system; patients not always have enough immune cells to use for therapy, and using cells from other ...

When a nerve is injured due to trauma or tumour resection, it would typically be cut off into two pieces, leaving an empty gap between them. Subsequently, this gap would cause permanent loss of nerve function (i.e. lack of sensation and movement). In 2020, 9,520 nerve injuries were reported in the UK for just upper limbs alone. Current treatments involve ...

INDUCE aims to develop and validate Sixfold's RNA therapeutics delivery system, MergoⓇ, for delivery of (simultaneously developed) short-interfering RNA (siRNA) gene silencing cargo to a specific tissue type (undisclosed). INDUCE brings together multidisciplinary, high-expertise partners with a track record of successful project completion, allowing for b...

There are an estimated 2.5 million people living with cancer in the UK, projected to increase up to 4 million by 2030\. Treatments and the outcomes for many cancers have improved, but not for rare, aggressive cancers such as Malignant Mesothelioma (MM). MM is an incurable cancer of the lining of the lung and chest (pleura) or abdominal cavity (peritoneum)...

Life-saving cancer treatment comes with many side effects that impact patients' quality of life, often for significant periods of time. Patients also suffer clinical signs such as liver or kidney toxicity, reduced immune function that increases risk of infection and even internal bleeding. This exerts a heavy cost on the National Health Service, related t...

SUMMIT aims to develop and validate Sixfold's oligonucleotide delivery system, MergoⓇ, for delivery of (simultaneously developed) short-interfering RNA (siRNA) gene silencing cargo to a specific tissue type (undisclosed). SUMMIT combines multidisciplinary partners with highly complementary expertise and experience in delivering successful projects, with r...

PROTECTING THE BRAIN IN PEOPLE WITH MULTIPLE SCLEROSIS (MS) * **MS** is a demyelinating autoimmune disease that attacks the brain, with year-on-year loss of brain volume, starting late teens and becoming manifest late twenties. There is no cure. Current therapies are immunosuppressive only. * The COVID-19 pandemic has spotlighted the vulnerable young incl...

While traditional pharmaceutical development of small-molecule and protein-based therapeutics can take years to reach patients, a more agile multi-disciplinary approach based on gene therapies has the potential to not only reduce time to market, but also improve therapeutic outcomes and reduce cost. This ability to rapidly engineer gene therapies has been...

At the time of initial application 15/April/2020, globally COVID-19 had infected over 1,914,916 people and killed over 123,010. Today, 22/October/2020, COVID-19 has infected over 41,104,946 and killed over 1,128,325. COVID-19 could wipe $4trillion from global economy and shrink UK economy triggering a 'big recession'. Epidemiologist prediction that a one-...

Though the monoclonal antibody (mAb), infliximab, is considered a gold-standard treatment for the 300,000 patients in the UK with inflammatory bowel disease (IBD), the compound can only be administered through an inconvenient and often painful injection. In doing so, only less than 1% of the drug reaches the site of disease, limiting the efficacy of the t...

"Cancer is the second leading cause of global mortality with over 8,000,000 deaths worldwide (WHO, 2015) and 163,444 in the UK (CRUK, 2014). There continues to be large unmet clinical need for patients with certain cancers such as ovarian where median survival is only 3 years. These survival rates have not changed for the past 3 decades. BioMoti, in a new...